Imaging solution developer Imagin Medical said today it launched the first-in-human study of its i/Blue Imaging System, with recruitment for the trial beginning at the University of Rochester Medical Center.
The company is developing the ultrasensitive i/Blue Imaging System which it hopes will “establish a new standard of care” for detecting certain cancers and visualizing the surgical field during minimally invasive surgery, with an initial focus on bladder cancer.
The newly launched study aims to explore the minimal dwell time needed for the detection of cancerous cells using protoporphyrin IX near infrared fluorescence, Imagin Medical said.
The company said it hopes the 10-patient study will show that surgeons are able to identify cancerous cells in less than 15 minutes, a significant reduction from the full hour of time required by current systems.
The study will also explore simultaneous acquisition of differing images which blends white light and fluorescing images into one step to enable the identification of cancerous cells within the bladder.
“We’re very excited. This is a major step toward improving bladder cancer detection for those whose lives are affected by this disease,” prez & CEO Jim Hutchens said in a press release.
Dr. Edward Messing of the University of Rochester Medical Center will act as principal investigator of the study, Imagin said.
